Traws Pharma Inc (TRAW)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.86M
Last updated: Nov 17, 2026 at 11:03 AM ET
Traws Pharma Inc (TRAW) Financials: Revenue, Profit and Cash Flow
Traws Pharma reported revenue of $2.79M for the fiscal year ended Dec 31, 2025, up 1134.5% from the year before. That year, net income was $9.17M with a net margin of 328.7%. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$3.55M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue fell from $5.55M, a compound annual decline of 7.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.79M | +1134.5% | 100.0% | -640.7% | 328.7% |
| Dec 2024 | $226.00K | 0.0% | 94.7% | -21835.4% | -24192.0% |
| Dec 2023 | $226.00K | 0.0% | 100.0% | -8981.4% | -8384.1% |
| Dec 2022 | $226.00K | 0.0% | 100.0% | -8684.5% | -8391.2% |
| Dec 2021 | $226.00K | -2.2% | 100.0% | -7299.1% | -7151.8% |
| Dec 2020 | $231.00K | -89.4% | 100.0% | -10819.5% | -10890.5% |
| Dec 2019 | $2.18M | +77.8% | 100.0% | -994.0% | -985.0% |
| Dec 2018 | $1.23M | +56.0% | 100.0% | -1895.9% | -1662.1% |
| Dec 2017 | $787.00K | -85.8% | 100.0% | -3270.3% | -3061.2% |
| Dec 2016 | $5.55M | N/A | 100.0% | -427.4% | -354.6% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.79M | $226.00K | $226.00K | $226.00K | $226.00K | $231.00K | $2.18M | $1.23M | $787.00K | $5.55M |
| Cost of revenue | $0 | $12.00K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $2.79M | $214.00K | $226.00K | $226.00K | $226.00K | $231.00K | $2.18M | $1.23M | $787.00K | $5.55M |
| Research and development | $12.14M | $130.31M | $11.43M | $11.41M | $7.30M | $16.90M | $15.54M | $16.92M | $19.12M | $20.07M |
| Operating income | -$17.88M | -$49.35M | -$20.30M | -$19.63M | -$16.50M | -$24.99M | -$21.70M | -$23.28M | -$25.74M | -$23.70M |
| Net income | $9.17M | -$54.67M | -$18.95M | -$18.96M | -$16.16M | -$25.16M | -$21.50M | -$20.41M | -$24.09M | -$19.67M |
| EBITDA | $8.75M | N/A | -$20.28M | -$18.95M | -$16.16M | N/A | -$21.48M | -$20.48M | -$24.02M | -$19.62M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2.62M | $0 | $2.73M | $57.00K | $57.00K | $57.00K | $57.00K | $56.00K | $56.00K |
| Gross profit | $0 | $0 | $0 | $2.62M | $0 | $2.73M | $57.00K | $55.00K | $57.00K | $57.00K | $56.00K | $56.00K |
| Operating income | -$3.60M | -$3.17M | -$6.95M | -$7.37M | -$4.05M | -$1.25M | -$5.20M | -$8.54M | -$8.54M | -$123.35M | -$5.21M | -$4.46M |
| Net income | -$3.55M | -$3.05M | -$7.11M | -$7.44M | -$3.96M | -$915.00K | $21.49M | -$8.47M | -$8.47M | -$123.14M | -$4.98M | -$4.18M |
Balance Sheet
As of Dec 2025, cash and equivalents of $3.82M were 36.0% of total assets of $10.62M, against total liabilities of $11.25M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10.62M | $24.96M | $22.68M | $39.37M | $55.48M | $19.99M | $23.67M | $17.92M | $4.98M | $23.23M |
| Current assets | $7.98M | $24.95M | $22.66M | $39.35M | $55.43M | $19.78M | $23.47M | $17.77M | $4.90M | $23.07M |
| Cash and equivalents | $3.82M | $21.34M | $20.82M | $38.76M | $55.07M | $19.02M | $22.73M | $16.97M | $4.02M | $21.45M |
| Total liabilities | $11.25M | $56.59M | $12.01M | $11.06M | $9.36M | $13.81M | $12.10M | $12.54M | $15.84M | $18.11M |
| Shareholder equity | -$629.00K | -$31.63M | $10.67M | $28.31M | $46.12M | $6.17M | $0 | $5.39M | -$11.69M | $4.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.52M | $11.47M | $8.16M | $10.62M | $12.44M | $15.62M | $19.06M | $24.96M | $8.94M | $18.69M | $18.17M | $22.68M |
| Total liabilities | $9.65M | $9.78M | $13.47M | $11.25M | $7.90M | $7.36M | $13.06M | $56.59M | $10.97M | $12.59M | $12.16M | $12.01M |
| Cash and equivalents | $2.34M | $5.02M | $3.13M | $3.82M | $6.42M | $13.08M | $15.94M | $21.34M | $5.41M | $16.89M | $16.39M | $20.82M |
| Shareholder equity | -$2.13M | $1.69M | -$5.31M | -$629.00K | $4.54M | $8.26M | $6.00M | -$31.63M | -$2.03M | -$105.52M | $6.01M | $10.67M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.79M | -$17.93M | -$16.29M | -$19.49M | -$23.07M | -$20.83M | -$22.70M | -$23.82M | -$15.81M | -$31.24M |
| Capital expenditures | $3.65M | $14.00K | $0 | $0 | $15.00K | $55.00K | $0 | $0 | $0 | $0 |
| Free cash flow | -$33.44M | -$17.95M | -$16.29M | -$19.49M | -$23.09M | -$20.89M | -$22.70M | -$23.82M | -$15.81M | -$31.24M |
| Investing cash flow | -$3.65M | -$14.00K | $0 | $0 | -$15.00K | -$55.00K | $0 | $0 | $0 | $0 |
| Financing cash flow | $33.98M | $0 | $0 | $55.56M | $19.36M | $26.65M | $35.66M | $6.36M | $17.42M | $7.46M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.48M | -$7.50M | -$2.58M | -$2.76M | -$4.01M | -$5.98M | -$5.44M | -$4.04M | -$11.48M | -$9.85M | -$4.42M | -$4.43M |
| Capital expenditures | N/A | N/A | $2.58M | $0 | $2.58M | $0 | $0 | $0 | $0 | $0 | $0 | $14.00K |
| Free cash flow | N/A | N/A | -$5.16M | -$2.76M | -$6.60M | -$5.98M | -$5.44M | -$4.04M | -$11.48M | -$9.85M | -$4.42M | -$4.44M |
Frequently Asked Questions About TRAW
What is Traws Pharma's annual revenue?
Traws Pharma reported revenue of $2.79M for the fiscal year ended Dec 31, 2025.
How fast is Traws Pharma's revenue growing?
Revenue was up 1134.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 131.1%.
Is Traws Pharma profitable?
Yes. Traws Pharma reported net income of $9.17M for the fiscal year ended Dec 31, 2025, with a net margin of 328.7%.
How much debt does Traws Pharma have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $3.82M.
What is TRAW's profit margin?
For the fiscal year ended Dec 31, 2025, Traws Pharma reported gross margin of 100.0%, operating margin of -640.7% and net margin of 328.7%.
TRAW pages: Overview, Earnings, Forecast, Financials, Competitors